Study S003382

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.

ClinicalTrials.gov record

Registration

Registration: NCT07239973
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 75
Start: 2025-10-24
Primary completion: 2026-03-05
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Conditions: Healthy; Non-diabetic Overweight or Obese
Interventions: DRUG:BGM0504 tablets; DRUG:Placebo tablets
Results posted: FALSE

Registered primary outcomes

Number of treatment adverse events [8 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.